**FY18 RESULTS**

**GAAP NET REVENUE** $15.8 BILLION

**PERFORMANCE NET INCOME PER SHARE**¹ $16.69

**CORE BUSINESS GREW 8.3%**
ON STRENGTH IN **MEDICAL AESTHETICS AND CENTRAL NERVOUS SYSTEM**²

**R&D PIPELINE ACHIEVED**
POSITIVE RESULTS IN 6 KEY LATE STAGE PROGRAMS INCLUDING CARIPRAZINE AND UBROGEPANT

**REDUCED DEBT BY $6.2 BILLION** AND EXECUTED $2.7 BILLION IN SHARE REPURCHASE PROGRAM

---

**GAAP REVENUE DRIVEN BY GROWTH IN TOP PROMOTED PRODUCTS:**

- **BOTOX**
- **Vraylar**
- **Juvederm**
- **Lo Loestrin Fe**
- **Linzess**

---

¹ Non-GAAP financial measure. Please refer to the GAAP to non-GAAP tables in January 29, 2019 Press Release on Allergan.com for a reconciliation of our non-GAAP results.

² Core Business = Promoted Brands & Brands with Ongoing Exclusivity + Other Product Revenue. Growth percentage vs. FY 2017, excluding FX.